8-K: Microbot Medical Secures $7 Million in Direct Offering and Private Placement

Microbot Medical has announced a $7 million capital raise through a registered direct offering and a concurrent private placement of preferred investment options.

Summary

• Microbot Medical Inc. has entered into agreements to sell 4,000,002 shares of common stock at $1.75 per share in a registered direct offering.
• The company is also issuing preferred investment options to purchase up to 8,000,004 shares of common stock at an exercise price of $1.75 per share in a concurrent private placement.
• The preferred investment options are exercisable immediately and expire two years from the issue date.
• The offerings are expected to close on or about January 7, 2025, pending customary closing conditions.
• H.C. Wainwright & Co. is the exclusive placement agent for these offerings.
• The company anticipates gross proceeds of approximately $7 million before deducting fees and expenses.

Sentiment

Score: 7

Explanation: The document is generally positive as it secures funding for the company's operations and development. However, there are risks associated with the offering and the company's future performance.

Positives

• The capital raise will provide Microbot Medical with approximately $7 million in gross proceeds.
• The funds will be used for the continued development, commercialization, and regulatory activities for the LIBERTY Robotic System.
• The company also plans to use the funds for expansion and development of additional applications from its IP portfolio.
• The preferred investment options provide a potential future source of capital if exercised.

Negatives

• The preferred investment options and underlying shares are not registered and have resale restrictions.
• The company will incur placement agent fees and other offering expenses, reducing the net proceeds.
• The exercise of the preferred investment options could dilute existing shareholders.

Risks

• The closing of the offerings is subject to customary closing conditions.
• The company's ability to obtain additional working capital is dependent on market conditions.
• There are risks inherent in the development and commercialization of the LIBERTY Endovascular Robotic Surgical System.
• Regulatory approvals, including FDA clearance, are uncertain.
• The company faces risks related to ongoing hostilities between Israel and the Palestinians.
• The company's ability to obtain future capital is not guaranteed.

Future Outlook

The company intends to use the net proceeds for the continued development, commercialization and regulatory activities for the LIBERTY Robotic System, expansion and development of additional applications derived from the Companys existing IP portfolio, and for working capital and other general corporate purposes.

Industry Context

This capital raise is typical for pre-commercial stage medical technology companies that require funding for research, development, and regulatory approvals. The use of a registered direct offering and private placement is a common strategy to secure capital from institutional investors.

Comparison to Industry Standards

• The use of a registered direct offering priced at-the-market is a common method for raising capital in the biotech and medical device sectors, allowing companies to access funds quickly.
• The concurrent private placement of preferred investment options is a strategy to attract investors who may be interested in potential future upside.
• The exercise price of $1.75 per share for both the direct offering and the preferred investment options provides a consistent valuation point.
• The two-year term for the preferred investment options is a standard timeframe for such instruments.
• The 7% placement agent fee is within the typical range for such transactions.

Stakeholder Impact

• Shareholders may experience dilution from the issuance of new shares and potential exercise of preferred investment options.
• Employees may benefit from the continued development and commercialization of the company's products.
• Customers may benefit from the development of the LIBERTY Robotic System.
• Suppliers and creditors may benefit from the company's improved financial position.

Next Steps

• The company will close the offerings on or about January 7, 2025.
• The company will use the net proceeds for the development and commercialization of the LIBERTY Robotic System.
• The company will file a final prospectus supplement with the SEC.
• The company will apply to list the shares and warrant shares on the Nasdaq Capital Market.

Key Dates

Keywords

Microbot Medical, registered direct offering, private placement, preferred investment options, common stock, LIBERTY Robotic System, H.C. Wainwright & Co., capital raise, medical technology, endovascular robotics